Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support
GlyPharma Therapeutics · Short Bowel Syndrome
Phase 1 / Phase 2
Completed
8
2024-10
Industry sponsor intelligence
GlyPharma TherapeuticsClinical Pipeline.
Lead-sponsor view of GlyPharma Therapeutics's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 3
- Recruiting
- 0
- Active
- 0
- Completed
- 2
- Results posted
- 0
- Avg enrollment
- 5
Pipeline overview
Programs by phase and activity.
Velocity
GlyPharma Therapeutics trials by start year
Study start year · indexed snapshot
Development
Trials by phase
6phase labels
Early Phase 10
Phase 13
Phase 23
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Apraglutide → | 3 | 3 | 3 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency
GlyPharma Therapeutics · SBS - Short Bowel Syndrome
Phase 1 / Phase 2
Completed
8
2024-10
Search sponsor records
All GlyPharma Therapeutics studies.
This page groups studies where GlyPharma Therapeutics is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
3 matching studies
Last registry update first
Recent updates